Biased Ligands. Better Drugs.

TRV027 Phase 2b trial design

Rationale and Design of the TRV027 Biased Ligand at the Angiotensin Receptor Study in Acute Heart Failure (BLAST-AHF). Presented at the 2014 European Society for Cardiology – Heart Failure meeting.

G. Michael Felker, Javed Butler, Sean Collins, Gad Cotter, Beth Davison, Gerasimos Filippatos, Phil Levy, Marco Metra, Piotr Ponikowski, David Soergel, John Teerlink, Adriaan Voors, Justin Ezekowitz, and Peter Pang.

View PDF

Copyright © Trevena, Inc.